Cerus Corporation

Cerus Corporation (NASDAQ:CERS) is a biomedical products company founded in 1991 and headquartered in Concord, California. The company went public in 1997 and has spent over three decades developing and commercializing blood safety technologies. Cerus operates as a specialized medical device company focused on pathogen reduction systems for blood transfusions, representing a critical niche within the broader healthcare industry. The company has evolved from a research-stage biotechnology firm into a commercial-stage enterprise with global operations, achieving its first profitable year in 2024 after years of development and market penetration efforts.

Over the past few years, Cerus has undergone significant strategic evolution from a development-stage company to a profitable commercial enterprise. The most significant milestone was achieving positive adjusted EBITDA for the first time in 2024, marking a fundamental shift in the company's financial trajectory after decades of losses. The company has focused heavily on expanding its commercial footprint, particularly in North America where it has captured nearly two-thirds of the U.S. platelet market. Major contract wins include securing long-term agreements with the American Red Cross and achieving 100% adoption by Canadian Blood Services. This commercial success has been supported by extending platelet shelf life to 7 days in some markets, improving the value proposition for blood centers. Product development initiatives have centered on expanding the INTERCEPT platform. The company has advanced its red blood cell system through Phase 3 clinical trials and is pursuing regulatory approvals in both the U.S. and Europe. Development of a new LED-based illumination device (INT200) represents a technological upgrade that received CE Mark approval in 2025, with plans for broader market rollout. The INTERCEPT Fibrinogen Complex (IFC) has emerged as a significant growth driver, with revenue growing 42% in 2024 to $9.2 million. The company has secured contracts with blood centers representing approximately 60% of the U.S. cryoprecipitate market and expanded its hospital-focused sales organization to drive adoption. International expansion has become a key strategic priority, with the company pursuing market entry in China (expecting NMPA approval in 2025), expanding in the Middle East and Saudi Arabia, and targeting opportunities in Germany. These efforts represent potential significant market expansion beyond the company's traditional North American and European markets. Manufacturing and supply chain optimization has been another focus area, with the company working to expand production capacity for IFC products and securing additional BLA approvals for manufacturing partners to enable broader distribution capabilities.